Prochlorperazine Increases KCC2 Function and Reduces Spasticity after Spinal Cord Injury

In mature neurons, low intracellular chloride level required for inhibition is maintained by the potassium-chloride cotransporter, KCC2. Impairment of Cl- extrusion after KCC2 dysfunction has been involved in many central nervous system disorders, such as seizures, neuropathic pain, or spasticity, a...

Full description

Bibliographic Details
Authors: Liabeuf, Sylvie|||0000-0002-8176-8657, Stuhl-Gourmand, Laetitia, Gackière, Florian, Mancuso, Renzo|||0000-0002-7046-3348, Sanchez-Brualla, Irene|||0000-0002-1992-150X, Marino, Philippe, Brocard, Frédéric|||0000-0001-9444-9586, Vinay, Laurent
Format: article
Publication Date:2017
Country:España
Institution:Universitat Autònoma de Barcelona
Repository:Dipòsit Digital de Documents de la UAB
Language:English
OAI Identifier:oai:ddd.uab.cat:321717
Online Access:https://ddd.uab.cat/record/321717
https://dx.doi.org/urn:doi:10.1089/neu.2017.5152
Access Level:Open access
Keyword:KCC2
Prochloperazine
Spasticity
Spinal cord injury
Description
Summary:In mature neurons, low intracellular chloride level required for inhibition is maintained by the potassium-chloride cotransporter, KCC2. Impairment of Cl- extrusion after KCC2 dysfunction has been involved in many central nervous system disorders, such as seizures, neuropathic pain, or spasticity, after a spinal cord injury (SCI). This makes KCC2 an appealing drug target for restoring Cl- homeostasis and inhibition in pathological conditions. In the present study, we screen the Prestwick Chemical Library® and identify conventional antipsychotics phenothiazine derivatives as enhancers of KCC2 activity. Among them, prochlorperazine hyperpolarizes the Cl- equilibrium potential in motoneurons of neonatal rats and restores the reciprocal inhibition post-SCI. The compound alleviates spasticity in chronic adult SCI rats with an efficacy equivalent to the antispastic agent, baclofen, and rescues the SCI-induced downregulation of KCC2 in motoneurons below the lesion. These pre-clinical data support prochlorperazine for a new therapeutic indication in the treatment of spasticity post-SCI and neurological disorders involving a KCC2 dysfunction.